Yes, there are blood tests specifically designed to detect cancer in dogs. These tests, often called liquid biopsies, work by analyzing a simple blood sample for biological signals that tumors release into the bloodstream. They’re commercially available through veterinary clinics right now, though they come with important limitations in what they can and can’t catch.
How These Tests Work
When cancer cells grow, divide, and die, they shed fragments of their DNA into the bloodstream. These fragments, known as circulating tumor DNA, mix with the normal cell-free DNA that all cells release. Cancer blood tests work by fishing out these tumor-specific fragments and identifying genetic alterations that healthy cells don’t carry, such as mutations, deletions, or rearrangements unique to cancer.
The two main commercial approaches differ in what they look for. One method uses next-generation sequencing to scan for multiple types of cancer-related genetic changes in cell-free DNA. The other measures levels of structures called nucleosomes, which are protein-DNA complexes that cancer cells release in abnormally high amounts. Both require only a standard blood draw at your vet’s office, with results typically returning from the lab within a few days.
What These Tests Can Detect
The sequencing-based liquid biopsy performs best against the most aggressive canine cancers: lymphoma, hemangiosarcoma, and osteosarcoma. Across these three cancer types, the test has demonstrated a sensitivity of 85.4%, meaning it correctly identifies cancer in roughly 85 out of 100 dogs that actually have one of these diseases. Other cancer types can also be detected, though with more variable results.
The nucleosome-based test (marketed as the Nu.Q Vet Cancer Test through IDEXX) covers seven common canine cancers but catches them at a lower overall rate of about 49.8% at 97% specificity. That specificity number matters: it means the test produces very few false alarms, but it will miss about half of dogs that do have cancer.
Neither test tells you exactly where in the body a tumor is located or how advanced it is. A positive result means cancer signals were found in the blood, but your vet will still need imaging, biopsies, or other diagnostics to pinpoint the type, location, and stage.
What a Negative Result Means
This is where understanding the limitations becomes critical. A negative result does not guarantee your dog is cancer-free. Sensitivity varies significantly by cancer type and stage. Early-stage cancers shed less DNA into the bloodstream, making them harder to detect. Some cancer types simply don’t release enough genetic material to trigger a positive reading.
Think of it this way: these tests are better at catching fast-growing, aggressive cancers that flood the blood with tumor DNA. Slower-growing or localized tumors may fly under the radar entirely. If your dog has symptoms that concern you, a negative blood test shouldn’t replace further workup with your veterinarian.
What a Positive Result Means
The high specificity of these tests (around 97 to 99% depending on the test) means false positives are uncommon. When the test says cancer signals are present, that finding is usually real. However, a positive result is a starting point, not a diagnosis. It tells you and your vet that something warrants investigation, and the next steps typically involve imaging like X-rays or ultrasound, and often a tissue biopsy to confirm the cancer type and plan treatment.
In some cases, the blood test may detect cancer before a dog shows any outward symptoms. This is the core appeal of screening: catching a malignancy early enough that treatment options are broader and outcomes are better.
When to Consider Screening
Research looking at over 3,000 dogs found that the median age of cancer diagnosis varies by breed and body size, which has practical implications for when screening makes sense. The general recommendation emerging from this data is to begin cancer screening for all dogs at age 7. For breeds known to develop cancer earlier (those with a median diagnosis age of 6 to 7 years), screening could start as early as age 4.
Larger dogs tend to be diagnosed with cancer at younger ages than smaller dogs. A weight-based formula from the same research estimates the median age at diagnosis drops by roughly 0.07 years for every additional pound of body weight. A 100-pound dog, for example, would have a predicted median diagnosis age several years younger than a 15-pound dog. A practical approach is to start screening about two years before the expected median age of diagnosis for your dog’s breed or size category.
Breeds with well-documented cancer predispositions, such as Golden Retrievers, Bernese Mountain Dogs, Rottweilers, and Boxers, are often considered the strongest candidates for routine screening. But any dog entering its senior years could potentially benefit, especially if early detection would change what you’d do about treatment.
Cost and Practical Considerations
These tests typically cost between $100 and $500 depending on the specific test and your veterinary clinic. They aren’t covered by most pet insurance plans when used as a screening tool, though coverage may apply when ordered as part of a diagnostic workup for a symptomatic dog.
The blood draw itself is quick and no more invasive than routine bloodwork your dog may already get at annual checkups. Some veterinarians offer cancer screening as an add-on to wellness visits, while others may recommend it only when there’s a clinical reason for concern.
Before ordering a screening test, it’s worth considering what you would do with the results. If a positive result would lead you to pursue further diagnostics and treatment, screening offers a genuine head start. If cost or other factors would limit your ability to follow up, the emotional weight of a positive result without a clear next step can be difficult to navigate.
How Blood Tests Compare to Traditional Diagnostics
Blood-based cancer screening doesn’t replace the standard diagnostic tools veterinarians already use. Physical exams, imaging, fine-needle aspirates, and tissue biopsies remain the backbone of cancer diagnosis in dogs. What liquid biopsies add is the possibility of detecting cancer before a lump is palpable or before symptoms appear.
For the three cancers these tests catch best, the irony is that lymphoma, hemangiosarcoma, and osteosarcoma are also among the cancers most commonly diagnosed through conventional methods. Lymphoma often shows up as swollen lymph nodes, hemangiosarcoma frequently presents as a sudden internal bleed, and osteosarcoma typically causes visible lameness and bone swelling. The value of blood-based detection is catching these diseases before they reach those more obvious, and often more advanced, stages.
Standard bloodwork panels that your vet runs during routine checkups (complete blood counts, chemistry panels) can sometimes raise red flags for cancer, such as elevated calcium levels or abnormal white blood cell counts. But these findings are nonspecific. The newer cancer-specific blood tests are designed to go further by identifying molecular evidence of a tumor rather than just its indirect effects on blood chemistry.